

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 1 | 1 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | — | 1 | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 1 | 1 |
| Stable angina | D060050 | — | I20.89 | — | — | — | — | 1 | 1 |
| Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Maxacalcitol |
| INN | maxacalcitol |
| Description | Maxacalcitol is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target vitamin D3 receptor. |
| Classification | Small molecule |
| Drug class | vitamin D analogs |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)OCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O |
| PDB | — |
| CAS-ID | 103909-75-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL333950 |
| ChEBI ID | — |
| PubChem CID | 12019456 |
| DrugBank | DB06272 |
| UNII ID | N2UJM5NBF6 (ChemIDplus, GSRS) |

